G
2.22
-0.04 (-1.77%)
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Grace Therapeutics, Inc. | Bercampur | Bercampur |
AISkor Stockmoo
2.5
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | 2.5 |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | 2.0 |
| Purata | 2.50 |
|
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage. Other products are GTx-102 Ataxia-Telangiectasia, GTx-101 Postherpetic Neuralgia, and GTx-201. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 28.15% |
| % Dimiliki oleh Institusi | 29.14% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Maven Securities Ltd | 30 Jun 2026 | 200,000 |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| KOHLI PRASHANT | 2.14 | - | 100,000 | 214,000 |
| OPALEYE MANAGEMENT INC. | 2.13 | - | 15,229 | 32,402 |
| Jumlah Keseluruhan Kuantiti Bersih | 115,229 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 246,402 | |||
| Purata Pembelian Keseluruhan ($) | 2.13 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| KOHLI PRASHANT | Pegawai | 09 Sep 2026 | Beli (+) | 100,000 | 2.14 | 214,000 |
| OPALEYE MANAGEMENT INC. | 09 Sep 2026 | Beli (+) | 5,836 | 2.14 | 12,489 | |
| OPALEYE MANAGEMENT INC. | 08 Sep 2026 | Beli (+) | 9,393 | 2.12 | 19,913 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |